Table 2 Frequency of loss of MMR proteins across tumors

78.2

82

12.1

15.9

77.2

11.5

MSI solid tumors

1057

[31]

N/A

N/A

N/A

N/A

3.7

1.8

GC

107

[253]

N/A

1.8

N/A

N/A

20.4

5.3

CRC

113

[254]

N/A

N/A

5.9

11.8

41.2

N/A

Undifferentiated GIC and PC

17

[255]

30.2

34.9

55.8

46.5

N/A

N/A

High-grade gliomas

355

[256]

7.1(partially negative)

7.1(partially negative)

7.1(partially negative)

7.1(partially negative)

N/A

N/A

Primary GBM

57

[257]

7.1(partially negative)

7.1(partially negative),7.1(completely negative)

14.3(partially negative),7.1(completely negative)

57.1(partially negative),28.6(completely negative)

N/A

N/A

Recurrent GBM

57

[257]

0.9

12.3

2.7

16.8

N/A

N/A

Prostate cancer

220

[258]

59.5

67.6

18.9

32.4

N/A

N/A

Endometrial endometrioid adenocarcinoma

107

[259]

23.8

N/A

14.8

9.3

N/A

N/A

Endometrioid endometrial carcinoma

486

[260]

83.34

3.33

1.37

4.11

N/A

N/A

CRC

1000

[261]

20

13.3

33.3

33.3

N/A

N/A

CRC,EC

15

[262]

23

N/A

N/A

N/A

N/A

N/A

pNETs

48

[263]

36

N/A

16

N/A

N/A

N/A

pNETs

55

[264]